Aptamer: Physiology and What Research Reports

What an aptamer is

An aptamer is a short, synthetic binding molecule that folds into a defined three-dimensional shape and recognises a chosen target — a protein, a small molecule, a cell-surface marker, or even a whole cell. Most aptamers described in the literature are single-stranded oligonucleotides (DNA or RNA) of roughly 20–100 bases. The word is also used in a second, narrower sense: a peptide aptamer is a short variable peptide loop displayed on a stable scaffold protein, designed to mimic the binding-loop function of an antibody without the antibody's size. Both senses share the same logic — a small, foldable polymer whose shape, not a fixed biological function, does the binding.

Because of that shared logic, aptamers turn up constantly in peptide and protein research: as capture reagents, as targeting "addresses" bolted onto larger constructs, and as the recognition element inside biosensors. Structural cataloguing of this molecular class is now formalised — a 2026 database report described Ribocentre-aptamer as an integrative, structure-focused database for RNA aptamers, assembling sequence and structural information in one resource (PMID 41118515).

Where aptamers come from: selection, not physiology

Unlike hormones or endogenous peptides, aptamers have no organ of origin. They are generated in vitro by iterative selection from very large random-sequence libraries, a process in which sequences that bind the target are retained and amplified while non-binders are washed away. The literature reports continuing engineering of that process itself: researchers described performing aptamer selection inside a porous hydrogel, a format the study reported as a way to compartmentalise and control the selection environment rather than relying on conventional bead or column partitioning (PMID 38065094).

Selection output is then triaged computationally. A 2017 review of aptamer bioinformatics surveyed the databases, sequence-analysis tools and structure-prediction approaches used to sort candidate sequences, cluster motifs and model binding, and reported that computational methods had become integral to modern aptamer discovery (PMID 29186809).

What aptamers do — and what has to be engineered

An aptamer's "function in the body" is whatever function its designers built in. Three recurring behaviours appear across the cited work.

Binding and targeted recognition

Some aptamers bind markers shared across many tumour cell types rather than a single lineage. A 2020 paper in Cancers described an aptamer characterised for broad cancer targeting and for therapeutic application, and researchers reported binding across multiple cancer cell types as the basis of that broad-targeting claim (PMID 33142831).

Stability in biological fluids

Naked oligonucleotides face nucleases and rapid clearance, so stabilisation is a central engineering problem. A 2022 study in ACS Nano reported that molecular engineering of aptamers into self-assembled structures increased in vivo stability and improved targeted recognition compared with the unassembled aptamer (PMID 34935348). Chemical robustness has also been selected for deliberately: a 2018 study reported alkaline-tolerant RNA aptamers that allowed acid-sensitive antibodies to be purified under neutral conditions, avoiding the low-pH elution step used in conventional affinity chromatography (PMID 29104137).

Switchable activity

Aptamers can be built to turn on or off. A 2014 PNAS study reported photoregulation of aptamer activity in living animals, using light to control when the aptamer engaged its target (PMID 25404344). At the sensor scale, a 2024 Analyst paper described intramolecular aptamer switches, in which target binding triggers a conformational change within the same molecule to generate a readable signal (PMID 38193253).

How aptamers are measured and studied

Aptamers are studied both as the object of measurement and as the measuring tool. Common approaches reported in the cited literature include:

• Binding and affinity assays — used during and after selection to rank candidate sequences, supported by the computational pipelines reviewed in 2017 (PMID 29186809).
• Structure curation — aggregated sequence-and-structure records, as assembled in the Ribocentre-aptamer database report (PMID 41118515).
• Sensing formats — a 2019 review in Trends in Analytical Chemistry surveyed engineering and sensing strategies for aptamer-based detection of small molecules, a target class that is difficult for antibodies (PMID 32863483).
• Imaging probes — a 2020 study reported an aptamer-based dual-modality probe combining fluorescent and radionuclide readouts in a single construct (PMID 32081705).

Aptamer, antibody, peptide: how the terms differ

Why the term matters in peptide and drug-delivery research

Readers who follow peptide science meet "aptamer" most often as a targeting module. A 2020 review in Advances in Biochemical Engineering/Biotechnology surveyed aptamer-modified nanoparticles for medical applications, describing how surface-displayed aptamers were used to direct particles toward specific cells (PMID 32157319). The same logic has been extended to nucleic acid therapeutics: a 2025 methods chapter described protocols for developing aptamer-targeted mRNA for immunotherapy, using the aptamer as the cell-recognition element of the delivery construct (PMID 40877519).

As a regulatory point of orientation, aptamer chemistry has reached clinical products — pegaptanib, an anti-VEGF RNA aptamer, is an approved ophthalmic drug — while the overwhelming majority of aptamers described in published work, including every construct in the papers cited here, are research reagents or preclinical candidates rather than approved medicines.

Tolerability and Limitations: What Studies Report

The cited literature is methodological and preclinical, and it does not establish a human safety profile for aptamers as a class. What researchers did report were engineering problems rather than clinical adverse events: insufficient stability of unmodified aptamers in biological environments, which the 2022 self-assembly study addressed by reporting improved in vivo stability and recognition after structural engineering (PMID 34935348); lack of temporal control over activity, which the 2014 study addressed by reporting light-triggered regulation in animals (PMID 25404344); and selection bottlenecks, which the 2023 hydrogel-selection study reported as the motivation for a new partitioning format (PMID 38065094). No dosing information is summarised here because the cited papers were selection, sensing, imaging and delivery studies rather than dose-ranging trials. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision.

References

• Aptamer Bioinformatics (International Journal of Molecular Sciences, 2017)
• Intramolecular aptamer switches (The Analyst, 2024)
• Ribocentre-aptamer: an integrative, structure-focused database for RNA aptamers (Nucleic Acids Research, 2026)
• An Aptamer for Broad Cancer Targeting and Therapy (Cancers, 2020)
• Developing Aptamer-Targeted mRNA for Immunotherapy (Methods in Molecular Biology, 2025)
• Aptamer-Modified Nanoparticles in Medical Applications (Advances in Biochemical Engineering/Biotechnology, 2020)
• Aptamer selection in a porous hydrogel (Cell Reports Methods, 2023)
• Aptamer photoregulation in vivo (PNAS, 2014)
• Innovative engineering and sensing strategies for aptamer-based small-molecule detection (Trends in Analytical Chemistry, 2019)
• Molecular Engineering of Aptamer Self-Assemblies Increases in Vivo Stability and Targeted Recognition (ACS Nano, 2022)
• Alkaline-tolerant RNA aptamers useful to purify acid-sensitive antibodies in neutral conditions (Biochimie, 2018)
• An aptamer-based, fluorescent and radionuclide dual-modality probe (Biochimie, 2020)